Cholangiocarcinoma is aheterogeneous disease which has a poor outcome that accountsfor 5%_10% with primary liver cancers. People characterizedits genomic and it is partially features and associatedthese with patient responses to treatments. We profiled the transcriptomes with 104surgically resected cholangiocarcinoma biological materials collectedfrom patients in Quarterly report, Europe, and theUnited States; epithelial and stromal compartmentsfrom 23 tumors were laser seize microdissected. Weanalyzed mutations in KRAS, epidermal growth factorreceptor (EGFR), and BRAF in samples with 69 tumors. Changes in gene expression were checked by immunoblottingand immunohistochemistry; integrativegenomics combined data from the patients with datafrom 7 human cholangiocarcinoma cell lines, whichwere then confronted with trastuzumab and lapatinib. People were classified into two subclasses, basedon 5-year survival rate (72% compared to 30%; _2 _ 11.61; P _. 0007), time to recurrence (13